biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Buys 6,874 Shares

biote Corp. (NASDAQ:BTMD - Get Free Report) major shareholder Guines Llc purchased 6,874 shares of the firm's stock in a transaction that occurred on Thursday, April 17th. The shares were acquired at an average cost of $3.29 per share, for a total transaction of $22,615.46. Following the purchase, the insider now owns 4,164,300 shares of the company's stock, valued at $13,700,547. This represents a 0.17 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Guines Llc also recently made the following trade(s):

• On Wednesday, April 9th, Guines Llc acquired 13,532 shares of biote stock. The shares were bought at an average price of $3.21 per share, for a total transaction of $43,437.72.
• On Monday, April 7th, Guines Llc bought 43,378 shares of biote stock. The shares were bought at an average cost of $3.15 per share, for a total transaction of $136,640.70.
• On Thursday, April 3rd, Guines Llc bought 7,321 shares of biote stock. The stock was purchased at an average cost of $3.24 per share, for a total transaction of $23,720.04.
• On Monday, March 31st, Guines Llc purchased 106,000 shares of biote stock. The shares were purchased at an average price of $3.32 per share, for a total transaction of $351,920.00.
• On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The stock was purchased at an average cost of $3.74 per share, with a total value of $374.00.
• On Thursday, March 13th, Guines Llc purchased 750,000 shares of biote stock. The stock was acquired at an average price of $3.22 per share, for a total transaction of $2,415,000.00.

biote Trading Up 1.1 %

Shares of NASDAQ BTMD traded up $0.04 during trading hours on Wednesday, reaching $3.52. The stock had a trading volume of 43,205 shares, compared to its average volume of 186,265. The business's fifty day moving average price is $3.88 and its two-hundred day moving average price is $5.09. The firm has a market cap of $192.58 million, a price-to-earnings ratio of 13.54 and a beta of 1.17. biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.44.

Analyst Upgrades and Downgrades

Separately, Craig Hallum cut their price objective on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th.

Hedge Funds Weigh In On biote

Several institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in shares of biote by 0.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock valued at $4,211,000 after purchasing an additional 3,065 shares in the last quarter. State Street Corp increased its holdings in shares of biote by 13.7% in the 3rd quarter. State Street Corp now owns 475,491 shares of the company's stock valued at $2,653,000 after acquiring an additional 57,290 shares during the period. Kanen Wealth Management LLC purchased a new stake in shares of biote during the 4th quarter worth $1,791,000. Northern Trust Corp boosted its position in biote by 9.9% during the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company's stock valued at $1,782,000 after purchasing an additional 25,873 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in biote in the fourth quarter valued at about $1,561,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.